Biphasic bullous pemphigoid starting after first dose and boosted by second dose of mRNA-1273 vaccine in an 84-year-old female with polymorbidity and polypharmacy.

Schmidt, V; Blum, R; Möhrenschlager, M

Schmidt, V; Blum, R; Möhrenschlager, M.

Schmidt V; Department of Dermatology, Hochgebirgsklinik Davos, Davos Wolfgang, Switzerland.
Blum R; Christine Kühne Center for Allergy Research and Education, Davos, Switzerland.
Möhrenschlager M; Department of Dermatology, Inselspital, University of Bern, Bern, Switzerland.

J Eur Acad Dermatol Venereol ; 36(2): e88-e90, 2022 Feb.

Article in English | MEDLINE | ID: covidwho-1449861

Subject(s)

2019-nCoV Vaccine mRNA-1273; Pemphigoid, Bullous; Aged, 80 and over; Female; Humans; Pemphigoid, Bullous/drug therapy; Polypharmacy

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pemphigoid, Bullous / 2019-nCoV Vaccine mRNA-1273 Type of study: Case report Topics: Vaccines Limits: Female / Humans Language: English Journal: J Eur Acad Dermatol Venereol Journal subject: Dermatology / Sexually Transmitted Diseases Year: 2022 Document Type: Article Affiliation country: Jdv.17722

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google